XFOR
X4 Pharmaceuticals Inc

3,644
Mkt Cap
$348M
Volume
883,693.00
52W High
$26.83
52W Low
$1.35
PE Ratio
-0.40
XFOR Fundamentals
Price
$3.98
Prev Close
$3.80
Open
$3.94
50D MA
$3.51
Beta
1.52
Avg. Volume
531,320.11
EPS (Annual)
-$5.59
P/B
1.62
Rev/Employee
$17,881.12
Loading...
Loading...
News
all
press releases
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research
Zacks Research lowered shares of X4 Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Wall Street Zen Upgrades X4 Pharmaceuticals (NASDAQ:XFOR) to "Hold"
Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·13d ago
News Placeholder
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +12.66% and -7.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Techne (TECH) Meets Q1 Earnings Estimates
Techne (TECH) delivered earnings and revenue surprises of 0.00% and -0.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial
The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.
Stocktwits·3mo ago
News Placeholder
X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target
The company said that the originally announced offering of $60 million was increased to $85 million to allow for the inclusion of an investor who had a pre-existing investment right.
Stocktwits·4mo ago
News Placeholder
X4 Pharmaceuticals Unveils Corporate Presentation for Investors
X4 Pharmaceuticals (XFOR) has shared an update. X4 Pharmaceuticals, Inc. has recently made their latest corporate presentation available to the pub...
TipRanks Financial Blog·1y ago
News Placeholder
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...
Globe Newswire·2y ago

Latest XFOR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.